A Cancer Test Has Investors Betting Big. But Will Insurers Pay?
An FDA panel backed Grail’s Galleri test. But the Medicare money the business depends on is far from guaranteed.
We haven't written up this one. WSJ Markets has the full story — the link below goes straight to it.